Background: In order to estimate the value of interventions in multiple sclerosis (MS) -where lifetime costs and outcomes cannot be observed -outcome data have to be combined with costs. This requires that cost data be regularly updated. Objective and methods: This study is part of a cross-sectional retrospective study in 16 European countries collecting current data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in 2015 Polish Zloty (PLN). Results: A total of 411 MS patients (mean age = 40 years) participated in Poland; 94% were below retirement age, and of these, 59% were employed. Employment was related to disability, and MS affected productivity for 85% of those working. Overall, 97% and 71% of patients experienced fatigue and cognition as important problems, respectively. Mean utility and total annual costs were 0.686 and 48,700 PLN at Expanded Disability Status Scale (EDSS) 0-3, 0.521 and 59,200 PLN at EDSS 4-6.5 and 0.208 and 81,600 PLN at EDSS 7-9, respectively. The average cost of a relapse was 3,900 PLN. Conclusion: This study illustrates the burden of MS on Polish patients and provides current data that are important for developing health policies.
Introduction
Health economic studies as part of policy and reimbursement decisions have been only recently implemented in Poland. Although draft guidelines for economic evaluation were developed as early as 2003, 1 studies became mandatory after legal changes were implemented in Poland in 2009 2 and in 2011. 3 However, some studies have been performed prior to this, including an early study of the cost of multiple sclerosis (MS). 4 The availability of disease-modifying treatments (DMTs) in MS has led to changes in the management of MS and to earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 5, 6 Approximately 40,000 people in Poland are estimated to have MS, with about 2000 new patients diagnosed annually. 7 These rates are based solely on the statistics provided by the National Health Fund (NFZ) and do not include various essential information such as the course and form of the disease, the degree of disability, the type of treatment, or data on patients' quality of life. The results from the Świętokrzyskie province, the regional centre for MS data collection, showed that in 2013, both the prevalence and the incidence in this region of Poland were higher than previously presented (109/100,000 population and 4.1/100,000 per year, respectively). 6, 7 Also, with faster diagnosis after a clinically isolated syndrome, 8 one must expect a different distribution of the MS form and disability levels, specifically a larger proportion of patients in the early stages of the disease and with less advanced disability (a low score on the Expanded Disability Status Scale (EDSS)).
It is therefore important to update the information on the burden of MS, and this study is part of a Europeanwide effort in 16 countries, endorsed by the European Platform of MS Societies (European Multiple Sclerosis Platform (EMSP)) and carried out with the support of national MS societies. 9 It uses a similar methodology as a previous European survey in 2005 which, however, did not include Poland. 10 
Materials and methods
The detailed methodology for the European survey is published separately as introduction to this series of country reports. 11 We therefore only provide a short summary of the general methods, noting issues specific to Poland.
Data
The study aimed to estimate all costs related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and medical tests, medication, community care, family support and production losses (sick leave, early retirement and disability invalidity). In addition, information on symptoms such as fatigue and cognition, health-related quality of life (HRQoL), as well as self-assessed disability using descriptions based on the Expanded Disability Status Scale (EDSS) was gathered.
Data were collected with a standard questionnaire at a single point in time for a retrospective period of time. The latter was varied depending on the question in order to minimise recall bias: 1 month for the use of drugs, community services and family help; 3 months for hospitalisation, consultations, medical tests, sick leave and relapses and 12 months for major investments (mobility aids and changes to the house or the car). Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol five dimensions (EQ-5D) 12 ), symptoms (fatigue and cognitive impairment) and the effect of MS on work related to the current day or week. For comparability across countries, 9 utility was estimated with the original value set developed in the United Kingdom. 13 However, since in Poland a local value set is available since 2010, 14, 15 these results are also presented.
Costs
Costs were calculated from the societal perspective, including all costs regardless of who ultimately is responsible for paying them. Patient co-payments and patients' out-of-pocket expenses are thus included.
The cost of a relapse was calculated as the difference in costs for a 3-month period for patients with or without a relapse and an EDSS score of 0-6, excluding resources unlikely to be directly affected by a relapse (invalidity, early retirement and DMTs). Patients who were unsure about relapses were excluded from the calculations.
Unit costs for the defined resource items were taken from public sources and are described more in detail in the paper on the study methodology. 11 Results are reported in Polish Zloty (100 PLN = €23.90 2015 average).
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented with sufficient numbers to permit analysis, rather than a prevalence sample. This highlights how costs and HRQoL change as the disease progresses and provides the necessary data for cost-effectiveness analysis of treatments that are expected to change the course of the disease. As a consequence, our study population does not represent the national prevalence of MS in Poland and mean results for the sample are not meaningful. They can neither be extrapolated to national costs without careful adjustment nor be compared directly to the results of other studies. We therefore report results by disease severity groups only (mild MS EDSS 0-3, moderate MS EDSS 4-6.5 and severe MS EDSS 7-9).
Data collection
In anonymous surveys, it is generally difficult to include a fully representative population, and changes in the management of MS, particularly earlier diagnosis, have increased this challenge. In addition, participation will depend heavily on the methods used for the survey: collecting data in clinical MS centres tends to overestimate the number of patients with early disease and on DMTs; 16 collecting data from members of patient organisations may lead to the opposite. Internet surveys will bias towards early disease and patients with higher education. In Poland, we collected data online from members of two patient organisations: the Polish MS Society and the Foundation NeuroPozytywni. A certain bias in our sample must therefore be expected.
The data were collected during a period of 6 months in 2015/2016 after approval by the ethics commission (Departament Nauki i Szkolnictwa Wyższego, Ministerstwo Zdrowia). The Polish Multiple Sclerosis Society (PTSR) invited patients to participate in the online survey by electronic mail on their website and other social media. No paper questionnaires were used due to personnel constraints in the organisation. The response rate was disappointing despite two reminders. We therefore invited additional participants via a neurological patient foundation (Fundacja NeuroPozytywni) with predominantly young members who provided around one quarter of the responses.
Results
A total of 411 evaluable responses were received online. All 16 geographical regions of Poland were represented, but 30% of respondents lived in the area of Warsaw that only represents 5% of the Polish population. Thus, our sample is biased towards an urban population, which is well-educated and has a high employment rate and easy access to health care and treatment. This is illustrated by the high proportion using DMTs: 54.5% in our sample compared to a national proportion of 20% estimated by the NFZ (AHTAPol: Verificative Analysis No. AOTM-OT 4351-4/2014, www.Aotm.gov.pl) and 25.6% reported in the preliminary analysis of results of the Polish register of MS Patients in the Świętokrzyskie province. 7 In addition, the average age of responders was lower than that of the average Polish MS patient population, which may partly be due to collecting data only online. We investigated whether it was possible to overcome this bias by excluding patients from the Foundation NeuroPozytywni or patients from the area of Warsaw, but we found no differences in age, education, or DMT usage. Thus, the bias affects the entire sample; one reason may be that patients treated under the NFZ programme were more likely and motivated to answer the survey. At the time of the survey, only about 20% of MS patients in Poland participated in this programme. The NFZ also offered regular visits in doctors' offices, obligatory annual magnetic resonance imaging (MRI) examination and laboratory tests, which might additionally affect the survey outcomes. The results of our Polish study must therefore be considered with the above limitations and might not necessarily represent the average population of Polish MS patients.
Within the European study, the Polish sample was among the youngest and least severely affected. 9 The majority of patients had relapsing disease (64%) and an EDSS between 0 and 3 (58%), and almost all were below retirement age (94%). The age and EDSS of patients will affect DMT treatment, the number of patients actually on DMTs, to some extent the proportion reporting a relapse and the proportion of patients of working age. Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in Poland ranged from 20 to 87 years (mean = 39.7, median = 38 and standard deviation (SD) = 12.3); women represented 74%; 83% lived with their family and only 1 patient was in a nursing home at the time of the survey. Education levels were higher than in the population: 1% of patients had basic, 40% had secondary or professional, and 59% university education. The latter is higher than in the general population (43% in the age group 30-34 years). 17 In part, this may be due to a misinterpretation by participants of the question, as it did not clearly ask for completed degree, in part due to the high proportion of participants from urban areas with more employment opportunities.
In the Polish sample, 387 patients were below retirement age, and of these, 59% patients were employed or self-employed. Six patients above retirement age also worked, bringing this group to 234 patients (57% of the entire sample) with a mean age of 36.9 years. This is only marginally lower than the rate of employment of 60.9% for women and 67.8% for the Polish population aged 20-64 years in 2015. 18 However, 74% of patients (n = 131) who were not employed indicated that this was due to MS. Assuming that without the disease these individuals would have been employed, workforce participation in this sample would be substantially above the national average, indicating again the bias towards a young urban population where MS impacts work severely. Also, all employed patients worked part time and 62% indicated that this was due to MS. The average weekly work time was 22.7 h for these patients, compared to 26.8 h for patients who worked part time for other reasons. For comparison, 6.6% of the general population have part-time employment. 19 Sick leave during the past 3 months was reported by 31% of patients, with a mean duration of 16.9 days. In the general Polish population, in the first quarter of 2015, sickness absence was reported only by 5% of insured persons, with a mean duration of 21 days, but in 54% of them sickness absence duration was ⩽10 days. 20 Employment decreased rapidly with advancing disease, as shown in Figure 1 .
Most employed patients felt that MS affected their productivity at work (85%), and only 8% indicated that they had no problems, while 7% had not answered this question. The severity of the impact covered the entire visual analogue scale (VAS) range from 1 to 10, with a mean of 3.4 (SD = 2.5), but 51% indicated a moderate score (1-3; Figure 2 ). Fatigue was considered the most disabling functional loss (84%), followed by low mood (42%), difficulties in thinking (38%), pain (36%), and mobility (13%).
Disease information
Data on disease characteristics are presented in Table  1 . The mean EDSS was 3.5 (SD = 2.3), but all levels of EDSS (except EDSS 9) were well represented. The mild groups represented 58% of the sample, the moderate group 29%, and the severe group 13%.
The proportion of patients with relapsing-remitting multiple sclerosis (RRMS) was 64% and with secondary progressive multiple sclerosis (SPMS) 15%. In view of the age of the sample, this distribution of MS forms could be expected. However, 18% of patients reported primary progressive multiple sclerosis (PPMS). This is high, particularly in view of the most recent data, 21 and might indicate difficulties for patients to distinguish between these two progressive disease types. Thus, we ignore the disease type in our analyses and focus instead on EDSS levels, despite the fact that DMTs are mostly indicated for relapsing disease.
The high proportion of patients with early relapsing disease may partly explain that DMTs were used by 55% of the sample, with usage declining as expected with higher EDSS levels (Table 1) . Among DMTs, first-generation drugs were used by 84% (Table 2) . This is a consequence of the fact that the use of DMTs in Poland is determined by the NFZ programme, and Mean scores on the visual analogue scales (0 = no problem; 10 = severe problems) for fatigue, cognitive difficulties, and impact of MS at work (only for patients working). Only 11 patients had no problems with fatigue (3 answers missing) and 121 patients had no cognitive difficulties, and these were assigned 0 for the estimation of the means. The effect of MS on productivity was estimated for employed patients only (17 answers missing); 19 patients indicated no effect and were assigned 0 for the calculation.
thus, some newer drugs are still not reimbursed (e.g. teriflunomide and alemtuzumab).
Relapses in the preceding 3 months were reported by 76 patients (18.5%), of which 50% occurred in the past month, and corticosteroid infusions were used in 49 patients. Of the respondents, 28% were unsure whether they had a relapse or not, and we assumed that the answer was no. The mean number of relapses over a period of 3 months in the sample was thus estimated at 0.2 (SD = 0.6).
Symptoms and HRQoL
Fatigue was reported as an important problem by 97% of patients who answered the VAS (n = 408). The mean VAS score for the entire sample was 5.3 and was correlated with disease severity measured by EDSS: 4.7, 5.9, and 6.5 for patients with mild, moderate, and severe disease, respectively ( Figure 2 ).
Similarly, a majority of patients felt that they suffered from cognitive difficulties (71%). The mean VAS score among this group with difficulties was 4.4 (SD = 2.3) and increased with disease severity: 4.1 in the mild and 4.8 in the moderate and severe groups.
For the entire study sample (assigning 0 to the group with no problems), the mean score was 3.2 (SD = 2.7) and 3.0, 3.4, and 3.0 in the three groups, respectively ( Figure 2 ).
All five domains of HRQoL included in the EQ-5D
represented problems for a majority of patients. Pain and anxiety represented problems for 78% and 75% of patients, usual activities for 63%, mobility for 61%, and self-care for 28%. As expected, difficulties increased with advancing disease. Self-care was only affected for patients with severe disease, while pain/discomfort and anxiety/depression are present already very early in the disease (Figure 3 ).
Utility
Utility scores were correlated with disability (EDSS; Figure 4 ). Mean utility in the sample was 0.576 and 0.738 using the UK and Polish value sets, respectively. The difference may be due to methodological differences in the development of the value sets or due to different preferences of the Polish population.
Resource utilisation
Resource utilisation is presented in Table 3 . Health care resources (except medication) were collected for a 3-month period. Hospitalisation was relatively frequent, with 21% of patients indicating an inpatient admission, most often to the neurology department, for an average of 1.5 times and a mean duration of 6.5 days. Day admissions occurred for 20% of patients, on average twice in the period. Rehabilitation centres were used by 12.5% of patients. Of the patients, 77% had consultations and 55.7% had investigations and medical tests (including MRI of the brain). Medication for MS or MS-related symptoms was used by 93% of patients during the past month; symptomatic prescription drugs (excluding corticosteroids) were used by 32%, most often spasticity or pain (21.7%) and depression (11.9%). Nonprescription drugs (over the counter (OTC)) were purchased by 77% of patients.
Investments in equipment and devices to aid patients' mobility were made during the past 12 months for or by 123 patients (29.9%), most often for walking aids and modifications to the car or the house (Table 3) .
Community services were only used by 7% of the patients during the past month, most often transportation. Considering that 90 patients in the sample had an EDSS of 6 and above, this may indicate insufficient availability of such services in Poland. However, help from family was provided for 53% of patients, on average 14.1 (SD = 11.4) days per month and 5.1 (SD = 6.0) hours per day. Informal care was, as EQ-5D: EuroQol-5 Dimensions; EDSS: Expanded Disability Status Scale. Utility by EDSS level estimated with the EQ-5D UK and Polish value sets. 10, 11 Utility is calculated by relating the scores of the five domains of the EQ-5D (1 = no problem, 2 = some problems, and 3 = severe problems) to a health state valuation system established with the general population. The difference between the two estimates is substantial, and is likely due to known methodological differences. 11 expected, concentrated in the group with severe disease ( Figure 5 ).
Costs
Total mean annual costs per patient for patients with mild, moderate and severe disease by EDSS are presented in Figure 6 and Table 4 .
The average cost of relapses during a 3-month period was estimated at 3900 PLN. All types of resources increased in the group of patients with relapses, with inpatient cost and day admissions representing 36% of the cost increase. Informal care and sick leave represented 30% and 13%, respectively, of the increase (Figure 7 ).
Discussion
The results of this study provide extensive information about the demographic, clinical and pharmacoeconomic situation of MS patients in Poland. The data have been generated by an online survey in a group of 411 MS patients coming from two patient organisations in Poland. The survey targeted mostly MS patients actively involved in patient affairs, who are young, well-educated, accustomed to electronic communication and from urban environments. These characteristics represent an important bias in our study that should be taken into consideration when Costs in our study are heavily dependent on the distribution of the sample over the EDSS range. In addition, although age is correlated with EDSS, it has an independent effect on production losses, as these are only relevant for patients below retirement age. In view of the young age and high proportion of patients with early disease, average costs per patient in the study are meaningless. We therefore present our results only by EDSS categories or in three groups of patients with mild, moderate and severe disease. As expected, costs increase with disease progression and higher disability.
For the same reason, it is difficult to compare our results directly with those of the earlier Polish study by Orlewska et al. 4 This small study in 148 patients was performed prospectively over 5 months and at a time when DMT availability in Poland was very limited. Not surprisingly, costs were vastly dominated by production losses, with a major increase in costs between the mild and moderate groups and a limited increase between the moderate and severe groups as patients had already left the workforce.
In this study, at the beginning of the disease, costs are almost exclusively incurred due to DMTs (89% of costs). Only when patients reach EDSS 4 or above, other resources such as hospitalisation, family help and productivity losses become more important. However, these calculations should be considered with caution, as we have used formal list prices for the DMTs, and during negotiations between health authorities and pharmaceutical companies, large discounts can be achieved. Unfortunately, these figures are not publicly available. The cost of DMTs in this study may thus be overestimated.
Another important piece of information derived from the survey data is the relatively low cost of community services in the total cost of MS patient care. This might indicate that this form of support for MS patients is not appropriately developed and organised in Poland. However, the cost of family support is high indicating the active involvement of families in patient care. This observation correlates with the traditional central role of family in social life in Poland.
In this survey, MS patients indicated that among many other symptoms, fatigue and cognition decline represent the most disturbing issues. This is an interesting observation since fatigue and cognition were considered as problems by a higher proportion of patients than mobility. In this context, one must remember, however, that overall mobility is different from self-assessed EDSS essentially based on ambulation. While the findings might again be related to the population of MS patients taking part in the survey, young patients with mild disability, they indicate that fatigue and cognition decline occur early in the disease course and significantly affect patients' self-perception about the disease, as well as their participation in work.
Utilities by EDSS level are consistently and considerably higher when using the Polish value set than when using the UK set. This is a consequence of methodological differences in the assessment of the health states to establish the tariff, resulting in higher utilities, and has been discussed by the authors of the value set. 14 In view of this, the authors concluded that for studies in Poland, the local tariff should be used. 14 For cost-effectiveness analyses in MS, where disease progression is the most important factor, the difference is less important as the two curves appear perfectly parallel. Indeed, a utility gain through slowing of disease progression is entirely based on the differences between the health states, not on the absolute values. 22 In conclusion, our study provides updated information on resource utilisation and costs of MS in Poland and confirms trends identified in earlier studies. However, it also highlights the importance of MS-related symptoms such as fatigue, cognition and pain and suggests that the impact of these symptoms on HRQoL, but also particularly on daily activities, workforce participation and support should be studied more in depth.
